Ethyl Ester
Evidence status
Limited evidence to recommend for any consumer outcome yet.
8 papers · 0 claims · 30 outcomes scored
Risk profile
Adverse events and known drug interactions
Safety events
nausea mild
Serious musculoskeletal events (including joint replacement)
Nonserious musculoskeletal adverse events
Nonserious infectious disease events
Sources
- 1. The effect of omega-3 Polyunsaturated Fatty Acid (PUFA) prescription preparations on the prevention of clinical cardiovascular disease: a meta-analysis of RCTs. (2024) ↑
- 2. Effects of niacin and omega-3 fatty acids on HDL-apolipoprotein A-I exchange in subjects with metabolic syndrome. (2024) ↑
- 3. A randomized clinical trial to determine the efficacy of manufacturers' recommended doses of omega-3 fatty acids from different sources in facilitating cardiovascular disease risk reduction. (2014) ↑
- 4. Effect of Eicosapentaenoic and Docosahexaenoic Acids Added to Statin Therapy on Coronary Artery Plaque in Patients With Coronary Artery Disease: A Randomized Clinical Trial. (2017) ↑
- 5. Effect of Omega-3 Acid Ethyl Esters on Left Ventricular Remodeling After Acute Myocardial Infarction: The OMEGA-REMODEL Randomized Clinical Trial. (2016) ↑
- 6. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials. (2014) ↑
- 7. Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial. (2012) ↑
- 8. Omega-3 Eicosapentaenoic Acid (EPA) Rich Extract from the Microalga Nannochloropsis Decreases Cholesterol in Healthy Individuals: A Double-Blind, Randomized, Placebo-Controlled, Three-Month Supplementation Study. (2020) ↑
Generated August 14, 2026